 1
Joseph A. Mollica, Chairman of the Board, Interim President & CEO Pharmacopeia John L. Higgins, President & CEO Ligand Pharmaceuticals The Oppenheimer 19th Annual Healthcare Conference New York City, November 3, 2008 Filed by Ligand Pharmaceuticals Incorporated Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-6 under the Securities Exchange Act of 1934, as amended Subject Company: Pharmacopeia, Inc. Commission File No: 0-50523 |
 Joseph
A. Mollica, Chairman of the Board, Interim President & CEO Discovering excellence, driving clinical success TM |
 3
This presentation, and oral statements made with respect to information contained
in this presentation, constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Such
forward-looking statements include those which express plan,
anticipation, intent, goal, contingency or future development and/or otherwise are not statements of historical fact. These statements are based upon management's current
expectations and are subject to risks and uncertainties, known and unknown,
which could cause actual results and developments to differ materially from
those expressed or implied in such statements. These forward-looking
statements include, but are not limited to, statements about the successful
implementation of Pharmacopeia's strategic plans and the merger transaction
between Pharmacopeia and Ligand Pharmaceuticals. Further information about these and other relevant risks and uncertainties may be found in Pharmacopeia’s Reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange
Commission. Pharmacopeia urges you to carefully review and consider the
disclosures found in its filings which are available in the SEC EDGAR database at http://www.sec.gov and from Pharmacopeia at http://www.pharmacopeia.com. All forward-looking statements in this
presentation and oral statements made with respect to information contained
in this presentation are qualified entirely by the cautionary statements included in this presentation and such filings. These risks and uncertainties could cause actual results to differ
materially from results expressed or implied by such forward-looking
statements. These forward-looking statements speak only as of the date
of this presentation. Pharmacopeia undertakes no obligation to (and
expressly disclaims any such obligation to) publicly update or revise the statements made herein or the risk factors that may relate thereto whether as a result
of new information, future events, or otherwise. Forward-Looking Statements |
 4
Pharmacopeia/Ligand Merger • Merger announced on September 24, 2008 • Expected to close Q4 2008/January 2009 • Pharmacopeia shareholders benefit from any growth of combined company • Exciting combined portfolio with significant royalty potential • Premium over Pharmacopeia stock price, including further upside through CVR if DARA is partnered • Pharmacopeia financing risk removed |
 5
Combined Product Pipeline Stage of Development Product Indication Partner Preclinical Phase I Phase II Phase III / NDA Marketed AVINZA ® Chronic pain King Pharmaceuticals PROMACTA™ ITP, Hep C, CLD, CIT GlaxoSmithKline VIVIANT™ / APRELA™ Osteoporosis Wyeth FABLYN® Osteoporosis Pfizer PS433540 DARA / Cardiovascular NA PS291822 COPD (CXCR2) Schering-Plough PS540446 Psoriasis / RA (p38) Bristol-Myers Squibb LGD-4665 Thrombocytopenia NA PS178990 Muscle Wasting (SARM) NA PS095760 Oncology Schering-Plough PS386113 Inflammation Schering-Plough PS948115 Respiratory Schering-Plough PS248288 Metabolic Diseases Schering-Plough PS873266 Inflammation Celgene LGD-4033 Muscle Wasting (SARM) NA Erythropoietin (EPO) Anemia NA AIPC Prostate Cancer NA PS031291 Arthritis/MS (CCR1) NA Ligand Products PS015146 Undisclosed Schering-Plough Pharmacopeia Products SGRM Inflammation & Cancer NA |
 John L.
Higgins, President & CEO Ligand Pharmaceuticals
|
 7
Safe Harbor Statement • The following presentation contains forward-looking statements regarding the proposed
acquisition of Pharmacopeia by Ligand, including projections regarding
expectations for potential research and development payments, savings in
operational costs, cash burn rates, timing of achieving positive cash flow,
and potential revenue and profits of a combined company. • The forward looking statements made in the presentation are subject to several risk
factors, including, but not limited to the reliance on collaborative
partners for milestone and royalty payments, regulatory hurdles facing
product candidates, uncertain product development costs, disputes regarding
ownership of intellectual property, the commercial success of approved
products. The failure of Pharmacopeia’s stockholders to approve the merger, Ligand’s or Pharmacopeia’s inability to satisfy the conditions of the merger, or that the merger is otherwise delayed or ultimately not consummated, and a failure of the combined
businesses to be integrated successfully. Additional risks may apply to
forward looking statements made in this presentation. • The risk factors facing Ligand and Pharmacopeia are explained in greater detail in the Company’s and Pharmacopeia’s filings with the SEC, including the most recently
filed annual reports on Form 10-K and quarterly reports on Form 10-Q,
as well as other public filings. |
 8
Additional Information and Where to Find It • Ligand filed on October 20, 2008, the SEC a preliminary Registration Statement on Form
S-4, which includes a proxy statement of Pharmacopeia and other relevant
materials in connection with the proposed transaction. Once, finalized, the proxy statement will be mailed to the stockholders of Pharmacopeia. Investors and
security holders of Pharmacopeia are urged to read the proxy statement and
the other relevant materials when they become available because they will contain important information about Ligand, Pharmacopeia and the proposed transaction. The proxy
statement and other relevant materials (when they become available), and any
other documents filed by Ligand or Pharmacopeia with the SEC, may be obtained free of charge at the SEC's web site at www.sec.gov. In addition, investors and
security holders may obtain free copies of the documents filed with the SEC by Ligand by going to Ligand’s Investor Relations website at www.ligand.com. Investors and security holders may obtain free copies of the documents filed with the
SEC by Pharmacopeia by going to Pharmacopeia’s Investor Relations page
on its corporate website at www.pharmacopeia.com. Investors and security holders of Pharmacopeia are urged to read the proxy statement and the other relevant materials
when they become available before making any voting or investment decision
with respect to the proposed transaction. • Ligand and its respective directors and executive officers may be deemed to be
participants in the solicitation of proxies from the stockholders of Pharmacopeia in favor of the proposed transaction. Information concerning Ligand’s directors and executive officers is set forth in Ligand’s proxy statement for its 2008 annual meeting of shareholders, which was filed with the SEC on April 29, 2008, and annual report on Form 10-K filed with the SEC on
March 5, 2008. • Pharmacopeia and its respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of Pharmacopeia in favor of the proposed transaction.
Information about Pharmacopeia’s executive officers and directors and
their ownership of Pharmacopeia common stock is set forth in the proxy statement for the Pharmacopeia 2008 annual meeting of shareholders, which was filed with the SEC on
March 24, 2008. Investors and security holders may obtain more detailed
information regarding the direct and indirect interests of Pharmacopeia and its respective executive officers and directors in the acquisition by reading the proxy
statement regarding the merger, which will be filed with the SEC.
|
 9
Why are we Acquiring Pharmacopeia? • Royalty partnerships • Drug discovery platform • Partnerable assets • Cash and tax assets |
 10 Vision for the Combined Companies • Consolidated operations with strong fundamentals Strong balance sheet Cost-efficient R&D business with spending discipline Robust product pipeline Diverse royalty partnerships with promising potential revenue and profits • Leverage highly successful drug discovery capabilities of both companies Focus on early stage drug discovery and development Partner pipeline assets at earliest value inflection point • Leadership focused on shareholders, market credibility and solid foundation • Commitment to driving shareholder value and to transparency on the business with
goal to drive strong cash flow and earnings |
 11 Combined Revenue Sources • AVINZA royalties • Potential royalties from three pending NDA’s and future registrations in
expanded indications PROMACTA (GSK) FABLYN (Pfizer) VIVIANT (Wyeth) APRELA NDA submission expected in 2009 (Wyeth) • Milestone and Research Payments from existing Pharmacopeia partnerships $6.5 to $25 million potential in 2009 • Potential new license payments from pipeline assets SARM, TPO, Oral EPO, SGRM, DARA, CCR1, JAK3 |
 12 Combined company will have one of the strongest, most diverse royalty partnership rosters in the small cap biotech universe Significant Value in Royalty Partnerships • Numerous deals with nine pharmaceutical companies • Over 15 programs in various stages of research and development in partnership portfolio • More than 20 different therapeutic indications being pursued including the largest
untapped markets Muscle wasting, COPD, thrombocytopenia, asthma • More than $400 million in potential R&D and milestone payments from existing
deals |
 13 Ligand’s Plan for DARA • Current 2009 plan Finish Phase IIb trial; spend minimal amount to complete study • Evaluate partnerability of DARA by focusing on: Quality of data Time and cost to develop drug and get it to market Patent extension options Terms of DARA agreement with BMS Interest level conveyed by past partnering discussions |
 14 Pro Forma Financial Forecast • Given our current outlook on the combined businesses, 2009 pro forma operating
cash burn rate is expected to be $20 million • Potential for additional revenue and cash infusion from new license agreements
• More than $350 million in potential Net Operating Loss carry-forwards before any
limitations Robustly capitalized company that has sufficient cash to make it to profitability without additional financings |
 15 Strong Research Platforms Mainly GPCR, kinase, ion channel, other targets Exclusively nuclear and cytokine receptor targets Targets Combinatorial chemistry compound library Over 7 million compound screening deck Discrete compounds 100,000 compound library Chemistry Broad approach similar to Big Pharma: -High-throughput & Ultra-HTS Screening Focused expertise: -Cell-based assays -Gene transcription Screening Pharmacopeia Ligand • Highly complementary research technology • Transaction combines two successful discovery platforms and integrates strong biology and chemistry capabilities |
 16 Opportunities and Benefits to Shareholders • Ligand shareholders gain access to: Numerous royalty partnerships Pipeline assets Drug discovery assets Cash and NOLs • Pharmacopeia shareholders will participate in: Lucrative potential near-term royalties Well capitalized company with no anticipated financing needs Expanded product pipeline Financial liquidity |
 17 Overview of Ligand’s Partnerships |
 18 Major Collaborations • 1997 drug discovery collaboration resulted in eltrombopag (PROMACTA) – small molecule TPO mimetic • ITP: Numerous clinical studies tested, data published in NEJM, NDA pending approval (16-0 panel vote in favor of drug) • Hepatitis C: Two Phase III trials were initiated in 4Q:07, Phase II Hep C data published in the NEJM • CIT: Chemotherapy-induced thrombocytopenia Phase II ongoing • Sarcoma: Phase I trial & |
 19 Thrombocytopenia - Causes of Disease • Decreased production of platelets Myelodysplastic syndrome Hepatitis C Cancer in the bone marrow (leukemia) Aplastic anemia • Increased destruction of platelets Autoimmune, such as ITP Sequestration in the spleen • Drug-induced Myelosuppression by chemotherapy regimens Anti-virals in Hep C therapies Thrombocytopenia is a condition in which there is an abnormally low level of platelets in the blood. Regardless of the underlying cause, thrombocytopenia leads to decreased platelet counts,
which puts patients at greater risk for bleeding and serious adverse
events. |
 20 Medical Significance of Thrombocytopenia (US) (Estimated markets) Potential Treatable Patients ITP ~100,000 Hepatitis C ~120,000 Myelodysplastic syndrome ~20,000 Leukemia / lymphoma ~50,000 Chemotherapy induced thrombocytopenia ~140,000 Intensive care unit – acquired ~500,000 Bone marrow transplants ~50,000 Lupus ~100,000 Cirrhosis ~113,000 HIV/other ~600,000 ~ 2 million platelet transfusions per year |
 21 Illustrative Cost for Blood-Related Treatments Annual Cost of Care Pharmaceuticals ~$15,000 (annual cost of care) Splenectomy $48,000 (procedure and medical management) Platelet Transfusion Single Course $4,000 Leukemia $84,000 (2 to 4 weeks daily) Bone Marrow Transplant $140,000 (4 to 6 weeks daily) Chemotherapy $20,000 (5 cycles) NPlate *$55,000 References: USRDS, 2005. DrugStore.com, Blood 108:481B-482B, 2006 American Red Cross, Transfusion of Plateles: Current Issues, Medical and Scientific
Updates, No 98-6. *Cost of therapy will be significantly higher if
increased dose is needed; Cowen & Company Analyst Report, August 29,
2008 |
 22 SERM Collaborations • Ligand has two partnerships around Selective Estrogen Receptor Modulators (SERMs): Wyeth Pfizer • SERMs bind with estrogen receptors in a tissue-specific manner: Exhibit estrogen action in some tissues and anti-estrogen action in other tissues Deliver benefits of estrogen in desirable tissues without the negative side effects • Potential target markets: osteoporosis, vaginal atrophy and vasomotor symptoms of menopause |
 23 SERM Collaborations & • Bazedoxifene (VIVIANT) Monotherapy: Received third FDA approvable letter for osteoporosis in May 2008 • Expects to file complete response with FDA by year-end Submitted NDA for osteoporosis treatment in 3Q:07 Submitted MAA for osteoporosis prevention
& treatment in 3Q:07 • Bazedoxifene in Combination with Premarin CE (APRELA): FDA Meeting in February 2008 discussed product formulation, bioequivalence and clinical study efforts to support the planned NDA filing. NDA planned by 2H:09 |
 24 SERM Collaborations • Lasofoxifene (FABLYN) for osteoporosis treatment • NDA pending approval; FDA Extended Review through January 2009 • FDA Panel had positive vote (9-3) on September 8, 2008 that benefits could outweigh its risks, including blood clots and vaginal bleeding for the osteoporosis treatment indication for FABLYN & |
 25 SARM Selective Androgen Receptor Modulators |
 26 SARM Program • Androgens (e.g. testosterone) are steroids that play key roles in bone, skeletal muscle and libido • Current androgenic drugs have disadvantages that significantly limit their use Non-selective stimulation of all androgen receptors Inconvenient formulations – injectable or topical Available oral drugs have potential for hepatotoxicity • Ligand’s lead SARMs LGD-3303 and LGD-4033: Tissue-selective for bone and muscle while sparing the prostate Orally active In preclinical development and expected IND filing in 4Q08 • Target Indications: osteoporosis, frailty,
hypogonadism, sexual dysfunction, cachexia Market Need • Convenient, prostate-sparing androgen receptor modulator with activity in bone, muscle and CNS |
 27 BMD Muscle Mass SARMs Address a Major Unmet Need Approximately 1/3 of Older Adults have low muscle mass and low bone mineral density Revue de Medecine Interne 2000; 21:608, Molecular Aspects Med. 2005; 26:818 Healthy Elderly Elderly with Serious Disease Epidemiology of Aging Ligand SARM Repletes Muscle and Bone Loss Increased falls Increased risk of fractures Normal Level Hormone Deficient |
 28 EPO Mimetic Program |
 29 Oral EPO Mimetics Will Provide New Therapeutic Options to Patients • Research-stage program to discover non-peptide, small molecule oral
agonists • Builds upon our recent success in discovering TPO mimetic drugs • Current recombinant EPO proteins and the EPO receptor synthetic peptides in development All require injection Minimal differentiation of products results in limited therapeutic option • Oral HIF Prolyl Hydroxylase inhibitors in development have the potential for mechanism-based toxicity HIF-induced angiogenesis is a risk • Oral EPO mimetics will potentially provide targeted activation of the EPO signaling pathway with an oral dosing route |
 30 TPO Mimetic Program |
 31 Ligand TPO Mimetic Program • The goal to develop best-in-class molecules to stimulate the production of platelets focused on: Potency Onset of action Safety Oral dosing flexibility • Ligand’s lead molecule, LGD-4665 has a promising efficacy and safety profile • Ligand is developing a robust library of next generation compounds |
 32 LGD-4665 Summary • LGD-4665 is approximately 10 times more potent than eltrombopag based on published data • The drug was safe and well tolerated in Phase I studies • The strong efficacy, good safety and long half-life may permit weekly dosing regimen • Conducting numerous pharmacology studies, to establish drug activity and differentiate drug profile from other TPO mimetic drug candidates • Conducting Phase II ITP trial |
 33 Combined Product Pipeline Stage of Development Product Indication Partner Preclinical Phase I Phase II Phase III / NDA Marketed AVINZA ® Chronic pain King Pharmaceuticals PROMACTA™ ITP, Hep C, CLD, CIT GlaxoSmithKline VIVIANT™ / APRELA™ Osteoporosis Wyeth FABLYN® Osteoporosis Pfizer PS433540 DARA / Cardiovascular NA PS291822 COPD (CXCR2) Schering-Plough PS540446 Psoriasis / RA (p38) Bristol-Myers Squibb LGD-4665 Thrombocytopenia NA PS178990 Muscle Wasting (SARM) NA PS095760 Oncology Schering-Plough PS386113 Inflammation Schering-Plough PS948115 Respiratory Schering-Plough PS248288 Metabolic Diseases Schering-Plough PS873266 Inflammation Celgene LGD-4033 Muscle Wasting (SARM) NA Erythropoietin (EPO) Anemia NA AIPC Prostate Cancer NA PS031291 Arthritis/MS (CCR1) NA Ligand Products PS015146 Undisclosed Schering-Plough Pharmacopeia Products SGRM Inflammation & Cancer NA |
 34 Near-Term Milestone and Events Calendar 1Q 09 FABLYN FDA Action 1Q 09 Phase IIb DARA 4Q 08 Completion of SP CXCR2 Trial in COPD 1Q 09 VIVIANT FDA Action 4Q 08 Phase II ITP Interim Data Projected Timing Development and Regulatory Events Ligand SARM IND Submission PROMACTA FDA Action 4Q 08 Anytime? |